A Rare and Atypical Case of Essential Cryoglobulinemic Glomerulonephritis with Crescents

Christopher Haas1*, Devinder Singh2, Pedram Kohan1, Suganthi Soundararajan1, and Sandeep Aggarwal4

1Drexel University College of Medicine, Philadelphia PA, USA
2Department of Medicine, Hahnemann University Hospital, Philadelphia PA, USA
3Department of Pathology, Hahnemann University Hospital, Philadelphia, PA, USA
4Department of Nephrology, Hahnemann University Hospital, Philadelphia, PA, USA

Abstract

We report a rare and atypical case of essential cryoglobulinemic glomerulonephritis with crescent formation in an 18yo African-American male that presented with recurrent microscopic hematuria, proteinuria, and mildly elevated creatinine. There was no antecedent history of purpura, rashes, or arthralgia/myalgia, and autoantibodies as well as viral serology for HCV, HIV, and CMV were negative. Quantification of serum immunoglobulins was significant for an elevated IgM without the presence of rheumatoid factor and elevated kappa and lambda light chains. Kidney biopsy demonstrated sclerosis, interstitial inflammation, endocapillary and mesangial proliferation, and crescent formation. Immunofluorescent studies demonstrated granular deposits within the glomerular basement membrane and mesangium. Electron microscopy revealed podocyte foot process effacement and the presence of mesangial and subendothelial dense deposits of randomly arranged, slightly curved microtubular/fibrillary structures that formed occasional fingerprints consistent with a diagnosis of cryoglobulinemic glomerulonephritis. The diagnosis was confirmed by the identification of serum cryoglobulins with subsequent immunofluorescence electron photomicrography of the cryoprecipitate revealing a mixed cryoglobulinemia type III. Treatment with IV methylprednisolone, followed by oral prednisone and Rituximab was initiated with resolution of hematuria and normalization of creatinine.

Keywords: Essential cryoglobulinemia; Glomerulonephritis; Cryoglobulinemic glomerulonephritis; Crescents; Clinical case

Introduction

Cryoglobulinemic glomerulonephritis is a rare and particular subtype of membranoproliferative glomerulonephritis that occurs following the deposition of cryoglobulins in the kidney [1-5]. It is specifically characterized by a variety of histopathological phenomenon including glomerular hypercellularity, increased cellular matrix, duplication of the glomerular basement membrane, inflammatory cell invasion, eosinophilic subendothelial deposits, and a characteristic pattern of immunohistological and ultrastructural findings on fluorescent and electron microscopy, respectively [1-4,6-9]. In a limited number of cases, cryoglobulinemic glomerulonephritis has been associated with crescent formation [3,10-12], a rare pathological phenomenon characterized by damage to the glomerular basement membrane and progressive scarring of the functional kidney unit, the nephron. On a structural level, this phenomenon involves a delicately orchestrated series of events including a sustained inflammatory reaction resulting in epithelial, mesangial, and endothelial cell proliferation, leukocyte and fibroblast invasion, and deposition of fibrin and collagen, leading to hematuria, proteinuria, and gradual loss of kidney function [13-18].

Though the pathophysiological mechanisms leading to the progressive decline of kidney function in the setting of membranoproliferative glomerulonephritis involve a myriad of factors, cryoglobulin-containing immune complex deposition is an inciting event. Cryoglobulinemia is often associated with lymphoproliferative disorders, such as multiple myeloma or Waldenstrom’s macroglobulinemia, connective tissue disorders, such as Systemic Lupus, or infectious etiologies, such as Hepatitis C, with the majority of cases manifesting in middle aged females in the 4th-5th decade of life [6]. In these cases a classical clinical triad of purpura, arthralgia, and weakness has been described [19-23], which generally precedes and progresses to renal involvement in approximately one-third of cases [24,25]. Intriguingly, in less than ten percent of cases no underlying cause for cryoglobulinemia has been found, and such cases have been termed ‘essential’ [21,23,26]. Furthermore, a rare subset of cases present with renal involvement in the form of microscopic hematuria or proteinuria, in the absence of systemic signs or symptoms [3,27]. In this report, we present a case of an 18y African-American male with recurrent microscopic hematuria and proteinuria, without other systemic symptoms, and who was found to have pathology consistent with cryoglobulinemic glomerulonephritis.

Case Presentation

An 18yo incarcerated African-American male with a past medical history significant for intermittent asthma presented to our hospital following repeated urinary dipsticks and urinalyses significant for hematuria and proteinuria found incidentally on routine laboratory studies dating from five months prior to admission. The patient denied significant symptomatology and also denied significant past medical/surgical history, medication use, or family history of renal disease or connective tissue diseases. The patient denied alcohol and illicit substance use, but assented to smoking approximately 1-2 cigarettes on a daily basis.

Throughout the course of hospitalization, the patient remained afebrile, maintained a heart rate of 60-70 bpm and a blood pressure that ranged from 110-135 systolic / 60-85 diastolic, and an oxygen saturation above 98%. On physical exam, the patient was a healthy appearing male with no acute distress, with no abnormalities appreciated. Of note, there were no oral ulcers, no observable rashes, petechiae, or purpura, no...
lymphadenopathy, no hepatosplenomegaly, no CVA tenderness, and no edema. Laboratory studies were performed and are reported in Table 1. Antibodies to ANCA, dsDNA, Glomerular Basement Membrane, SS-A, SS-B, Smith, RNP, Scleroderma (ScI70), Rheumatoid Factor, Anti-Streptolysin O, and Anti-cyclic Citrullinated Peptide (CCP) were all negative. Hepatitis B and Hepatitis C panel (antigens and antibodies) were non-reactive and there was no evidence of viral titers. HIV status and TB was also negative. Immunoglobulins of the IgG subtype were elevated to EBV Viral Capsid Antigen and Nuclear antigen, however EBV IgM and early IgG antibodies, as well as viral DNA PCR analyses, were negative, consistent with prior infection. Levels of serum immunoglobulins of the IgM subtype as well as kappa and lambda light chains were elevated. Serum protein electrophoresis was significant only for decreased albumin without any abnormalities in total globulin, alpha globulins, beta globulins, gamma globulins, or the presence of an M-spike. Analyses for cryoglobulins were positive at 72 hours, with resultant cryoprecipitate immunofixation electrophoresis revealing a type III mixed cryoglobulinemia. Total complement, C3, and C4 were all within normal limits.

Urine analyses included a urine dip, microscopy, urine chemistry, and 24h urine electrophoresis. Urine dip was significant for the presence of 2+ protein and 3+ blood in the setting of a urine specific gravity of 1.013, with 31-50 RBC and 1-4 hyaline casts/hpf on microscopic analysis. Urine chemistry and urine protein electrophoresis were significant only for the presence of elevated protein. Random urinary protein to creatinine ratio at presentation was 1.60, serving as a surrogate marker of daily protein excretion. Urine drug screen was negative for illicit substances.

Bilateral renal ultrasound with color Doppler imaging revealed normally sized kidneys with increased cortical echogenicity and no evidence of hydronephrosis, contour-deforming masses, calculi, or perinephric fluid accumulations. The patient subsequently underwent a percutaneous ultrasound guided biopsy of the left kidney, with specimens sent for histological, immunological, and electron microscopy analysis. Light microscopy of HE stained sections revealed moderate interstitial fibrosis, tubular atrophy, and mixed interstitial inflammation composed of lymphocytes, plasma cells, neutrophils, eosinophils, and rare macrophages. Thirty-two glomeruli were identified, of which the vast majority were enlarged with fibrinoid necrosis and pyknotic nuclei, while the remainder were sclerosed. Immunofluorescence staining for IgG, IgM, C3, C1q and kappa light chains with mild staining for lambda light chains were positive, revealing the presence of granular deposits that were strongly positive for IgG, IgM, C3, C1q and kappa light chains with mild staining for IgA, C4, and lambda light chains (Figure 1). Electron microscopy revealed effacement of over 80% of podocyte foot processes and the presence of substantial subendothelial electron dense deposits of randomly arranged, slightly curved microtubular/ fibrillary structures 20-20.5 nm in diameter that formed occasional fingerprints (Figure 4). Taken together, the spectrum of clinical and pathological findings was suggestive of a diagnosis of membranoproliferative glomerulonephritis secondary to cryoglobulinemia (cryoglobulinemic glomerulonephritis).

Outcome and Follow-Up

The patient was loaded with IV methylprednisolone 500 mg daily for three days and subsequently received 60 mg prednisone and 1000 mg Rituximab. Flow cytometry following Rituximab administration revealed no immunophenotypically abnormal cell populations with a complete absence of CD20+ cells. One month following admission the patient presented for a second course of Rituximab therapy and was then found to have diminished microscopic hematuria (11-20 RBC/hpf), diminished urinary protein (191 mg/dL) to creatinine (189 mg/dL) ratio of 1.01 from 1.60, and stabilization of his serum creatinine (1.21 mg/dL). Repeat analysis three months following initial presentation revealed a sustained suppression of CD20+ B cells and continued improvement in laboratory parameters with further reductions in microscopic hematuria (6-11 RBC/hpf) and serum creatinine (1.00 mg/dL).

Discussion

In the most straightforward terms, cryoglobulinemia is defined as the presence of cryoglobulins in the blood [6]. In the clinical laboratory setting, cryoglobulins immunoglobulins that undergo reversible precipitation following exposure to cold temperature [26], assuming appropriate and strict handling techniques [26,28]. In reality, however, the precipitation of cryoglobulins and their deposition in situ likely involves a complex interplay of a variety of factors affecting protein solubility – primary protein structure, abundance of hydrophobic residues, steric conformation, decreased galactose or sialic acid in glycosylated regions, serum pH, serum chloride concentration, and immune complex formation [21,26,28]. The deposition of these immune complexes in end organs has been shown to mediate end organ damage via a variety of different mechanisms including activation of innate Toll-like receptors, complement, and engagement of Fc receptors. Together, activation of these pathways results in propagation of an inflammatory cascade leading to cellular injury and the secretion of growth factors, such as PDGF and TGFβ, that promote epithelial cell proliferation and matrix deposition [1,14,16-18,33]. Furthermore, monocytes appear to play a critical role in the clearance of deposited cryoglobulins and are often found not only in close proximity to such deposits, but also to be laden with amorphous protein droplets [34], prompting one study to highlight the potential for monocye dysfunction as an underlying etiology of end organ damage [11,35].

Brouet and colleagues have classified cryoglobulinemia into three main categories, with the latter two categories classified as “mixed cryoglobulinemia” due to the presence of multiple antibodies [6,25]. Type I cryoglobulinemia is a monoclonal immunoglobulinemia commonly found in multiple myeloma, Waldenstrom's macroglobulinemia, or idiopathic monoclonal gammopathy, whereas the Type II and Type III mixed cryoglobulinemias contain monoclonal IgM and polyclonal IgG or polyclonal IgM and polyclonal IgG, respectively [25]. Mixed cryoglobulinemia has been associated with a variety of etiological factors - autoimmune (e.g. Systemic lupus erythematosus and Sjogrens Syndrome) and infection (e.g. HCV) - with less than 10% of cases labeled as 'essential,' with no underlying etiology. Despite the absence of an underlying etiology, a variety of reports have suggested that cryoglobulinemia is a disorder of B lymphocyte expansion, whether in the context of lymphoproliferative disorders or in the context of persistent immune stimulation in the setting of autoimmunity or chronic infection [1,21,36]. Infection with Epstein Barr Virus (EBV) and the production of IgG subtype antibodies to the viral capsid antigen, as seen in our patient, was also seen in patients with essential mixed cryoglobulinemia [36]. Furthermore Fiorini and colleagues hypothesized that not only are EBV-infected B lymphocytes cleared more slowly, resulting in a greater number of antigen-bearing cells that
### Serum Chemistry

| Parameter                  | Value  |
|----------------------------|--------|
| Sodium                     | 137 mmol/L |
| Potassium                  | 4.1 mmol/L |
| Chloride                   | 102 mmol/L |
| CO₂                        | 28 mmol/L |
| Calcium                    | 9.3 mg/dL |
| Blood Urea Nitrogen        | 17 mg/dL |
| Creatinine                 | 1.23 mg/dL |
| Total Protein              | 7.5 g/dL |
| Albumin                    | 3.2 g/dL (L) |
| Bilirubin Total            | 0.32 mg/dL |
| Alkaline Phosphatase       | 37 IU/L |
| ALT                        | 10 IU/L |
| AST                        | 22 IU/L |
| Magnesium                  | 1.8 mg/dL |
| Phosphate                  | 3.0 mg/dL |
| Iron                       | 47 mcg/dL |
| Total Iron Binding Capacity| 305 ng/mL |
| Ferritin                   | 108 ng/dL |
| Transferrin                | 218 mg/dL |
| CRP                        | 4.1 mg/L |
| ESR                        | 49 mm/hr |

### Coagulation Studies

| Parameter                  | Value  |
|----------------------------|--------|
| PT                         | 11.8s  |
| PTT                        | 37.2s  |
| INR                        | 1.09   |
| C3 complement              | 149 mg/dL |
| C4 complement              | 30 mg/dL |
| Total Complement           | 49 Units/mL |
| Fibrinogen                 | 464 mg/dL |

### Immunology/ Serology

| Parameter                                      | Value  |
|-----------------------------------------------|--------|
| Anti-streptolysin O                           | 77.9 IN Units/mL |
| Atypical p-ANCA                               | <1.20  |
| Cytoplasmic C-ANCA                            | <1.20  |
| Perinuclear P-ANCA                            | <1.20  |
| Glomerular Basement Membrane Antibody         | 7 Units |
| Cyclic Citrullinated Peptide IgG/ IgA         | 10 Units |
| Antinuclear (ANA) Screen                      | Negative |
| Scleroderma CL70                              | 0.2 Units |
| Smooth Muscle                                 | 6 Units |
| Double-stranded DNA                           | 4 IU   |
| SS-A                                          | <0.2 Units |
| SS-B                                          | 0.4 Units |
| Ribonuclear Protein                           | <0.2 Units |
| Rheumatoid Factor                             | <10 IU/mL |
| Smith                                         | <0.2 |
| Immunoglobulin A                              | 268 mg/dL |
| Immunoglobulin G                              | 1580 mg/dL |
| Immunoglobulin M                              | 518 mg/dL (H) |
| CMV DNA Quant                                 | <200 copies |
| EBV Early IgG                                 | <9 Units/mL |
| EBV Viral Capsid Antigen IgM                  | <36 Units/mL |
| EBV Viral Capsid Antigen IgG                  | 97.9 Units/mL (H) |
| EBV Nuclear IgG                               | 155 Units/mL (H) |
| EBV DNA PCR RT                                | Negative |
| Hepatitis A IgM                              | Non-reactive |
| Hepatitis B Surface Antigen                   | Non-reactive |
provide a continuous stimulus for antibody production [6,36], but also that EBV viral DNA is incorporated into marrow blasts, providing a continuous reservoir for chronic, recurrent infection and cryoglobulin production [34,37].

The prevalence of ‘essential’ mixed cryoglobulinemia has been reported to be less than 1:100,000 [1,38] and is characterized as a myriad of clinical manifestations including purpura, arthralgia and weakness, with variable end-organ involvement [1,6,21,38]. Renal involvement takes an indolent course, presenting with microscopic hematuria, proteinuria, and an elevated serum creatinine in approximately 50% of patients [11,21-23,26,34,38]. Histologically, renal involvement manifests as a particular subtype of membranoproliferative glomerulonephritis in the setting of systemic symptoms, but rare cases, present with renal disease as the sole manifestation of the disease [3,6,10], as seen in our patient. Furthermore, a small number of reports have demonstrated crescent formation on the background a cryoglobulinemic glomerulonephritis, a hallmark of severe disease [3,10,11,13,21].

The diagnosis of mixed cryoglobulemia revolves around
characteristic clinical (e.g. purpura, arthritis, and glomerulonephritis) and laboratory findings (e.g. isolation of cryoglobulins, low levels of C4 and C1q, and high titers of rheumatoid factor) [6,21]. A variety of reports, however, have noted variable serological patterns [38] ranging from the complete absence of serum cryoglobulins [34,38-40] to completely normal levels of complement proteins [3]. Of note, it has been demonstrated that levels of cryoglobulins can fluctuate significantly resulting in the potential for false-negative results, making serial assays necessary for proper diagnosis [21,26,28]. Intriguingly, four initial serum samples for cryoglobulins were negative, whereas a fifth sample demonstrated the presence of cryoglobulins at 72 hours of incubation, highlighting the need to repeat laboratory analyses in the setting of high clinical suspicion. It is important to recognize that in cases where the clinical suspicion for cryoglobulinemia is high, a negative test for cryoglobulins does not exclude a diagnosis of cryoglobulinemia [21,28].

The course of cryoglobulinemic glomerulonephritis is variable. One-third of patients achieve partial or complete remission, another third have an indolent disease course that may progress to renal insufficiency years later, while one-third experience reversible clinical exacerbations even in the setting of appropriate treatment [3,34]. Progression to end stage renal disease and sclerosing nephritis has been reported as an uncommon event [10]. Though a variety of prognostic indicators have been proposed as independent risk factors for progression to end stage renal disease and mortality – older age, purpura, elevated plasma creatinine on presentation, and low C3, the subjects of this study were primarily Italian, middle-aged, co-infected with HCV, and had systemic signs of disease [10]. The patient in this case report, in contrast, was a young African-American male who presented with recurrent microscopic hematuria and proteinuria in the absence of systemic signs or symptoms, a negative HCV status, and normal complement levels. Furthermore, on renal biopsy the patient was noted to have significant crescent formation as well as focal and global glomerulosclerosis in 25% of his glomeruli at presentation, suggesting a more advanced disease process. Intriguingly, mixed cryoglobulinemia has been regarded as continuum along a spectrum
that spans autoimmunity/ persistent infection and cancer [21,41], with B cell lymphoma the most frequent neoplastic manifestation [3,21-23,38,42,43]. In these studies, lymphomas were found to arise in the setting of persistent B lymphocyte infection, such as in the setting of chronic infection and also due to lymphocytic infiltration in major organs, such as the bone marrow [41,42,44] and heralded by a sudden decrease or disappearance of serum cryoglobulins [45]. Given the potential for malignant transformation, repeated longitudinal clinical evaluation is warranted.

Though no clinical trial has evaluated their efficacy, the mainstay of therapy for individuals with cryoglobulinic glomerulonephritis has been the use of high dose conventional immunosuppressants such as methylprednisolone followed by prednisone [21,38,46]. In an increasing number of cases biological therapies, targeting specific aspects of disease pathogenesis, have emerged as concomitant first line therapies. Given the intricate link between mixed cryoglobulinemia and aberrant B lymphocyte antibody production, proliferation, and elimination, the anti-CD20 monoclonal antibody, Rituximab, has been frequently used to control disease. A variety of small reports have demonstrated clinical efficacy in the setting of moderate disease and have highlighted that relapses recur in the setting of B lymphocyte recovery [13,32,47,48]. The patient presented in this report received successful Rituximab therapy that led to a complete elimination of peripheral CD20+ B lymphocytes, as verified by flow cytometry. In addition to conventional therapy, a variety of other interventions targeting improved monocyte clearance of circulating cryoglobulins and deposited complexes of cryoglobulins, via dietary modification, and reduction of intraglomerular filtration pressure, via ACE inhibitors, have been proposed [30,38], and require further evaluation in carefully designed clinical trials.

Conclusion

The patient in this report represented a rare and atypical case of cryoglobulinic glomerulonephritis. The uniqueness of this case is underscored by a variety of factors such as his clinical presentation, laboratory and serological studies, and pathology. In contrast to the vast majority of patients with cryoglobulinemia that present with systemic manifestations of cryoglobulinemia, the subject of this report did not have the classic clinical triad of purpura, arthralgia, or weakness. In contrast, the patient was of the minority of patients presenting with renal involvement, characterized a persistent microscopic hematuria and proteinuria as the presenting symptom. Furthermore, while the overwhelming majority of patients presenting with cryoglobulinemia are middle-aged Caucasian females, our patient was an 18yo African-American male without an underlying etiology for cryoglobulinemia. Only a single prior report has demonstrated a diagnosis of cryoglobulinemia in a patient under 20y [6,49]. Laboratory and serological studies in cryoglobulinemia generally follow a characteristic pattern – detection of circulating cryoglobulins, low levels of complement, and the presence of rheumatoid factor - yet a limited number of cases have presented with varied serological results, similar to the case presented here. Pathological analysis of kidney biopsy samples obtained from our patient demonstrated findings consistent with cryoglobulinemic glomerulonephritis on light, immunofluorescent, and electron microscopy. Importantly histological specimens also demonstrated the presence of a significant number of crescents, a rare pathological finding in the context of cryoglobulinemia and cryoglobulinemic glomerulonephritis. In sum, the case presented here represented a particular diagnostic challenge that required the coordinated efforts of internal medicine, nephrology, and pathology to accurately diagnose and formulate a therapeutic regimen to prevent further decline in kidney function.

Consent

Informed consent has been obtained from the patient to write this manuscript

Conflict of interest

The authors have no conflicts of interest to declare

References

1. Kowalewska J (2011) Cryoglobulinic glomerulonephritis—lessons from animal models. Folia Histochem Cytobiol 49: 537-546.
2. Mazzucco G, Monga G, Casanova S, Cagnoli L (1986) Cell interposition in glomerular capillary walls in cryoglobulinic glomerulonephritis (CRYGN). Ultrastructural investigation of 23 cases. Ultrastruct Pathol 10: 355-361.
3. Maligron M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, et al. (2009) Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore) 88: 341-348.
4. Monga G, Mazzucco G, Casanova S, Boero R, Cagnoli L, et al., Ultrastructural glomerular findings in cryoglobulinic glomerulonephritis. Appl Pathol 5: 108-115.
5. D’Amico G, Colasanti G, Ferrari F, Sinico AR, Bucci A, et al. (1988) Renal involvement in essential mixed cryoglobulinemia: a peculiar type of immune-mediated renal disease. Adv Nephrol Necker Hosp 17: 219-239.
6. Cordomier DJ, Rerverse JC, Viatell P, Dechelette E (1987) The kidney in mixed cryoglobulinemias. Springer Semin Immunopathol 9: 385-415.
7. Feiner H, Gallo G (1977) Ultrastructure in glomerulonephritis associated with cryoglobulinemia. A report of six cases and review of the literature. Am J Pathol 85: 145-162.
8. Fabbian F, Stabellini N, Galdi A, Sartori S, Aleotti A, et al. (2008) Ultrastructural pathology of nephropathies with organized deposits: a case series. Cases J 1: 184.
9. Iskandar SS, Herrera GA (2002) Glomerulopathies with organized deposits. Semin Diag Pathol 19: 116-132.
10. Tarantina A, Campise M, Barni G, Confalonieri R, Bucci A, et al. (1995) Long-term predictors of survival in essential mixed cryoglobulinic glomerulonephritis. Kidney Int 47: 618-623.
11. Beddu S, Bastacky S, Johnson JP (2002) The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 81: 398-409.
12. Tsuboi N, Ichinose M, Kawanura T, Joh K, Utsunomiya Y, et al. (2010) Rapidly progressive cryoglobulinic glomerulonephritis. Clin Exp Nephrol 14: 492-495.
13. Moroni G, Ponticelli C (2014) Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev 13: 723-729.
14. Atkins RC, Nikolic-Paterson DJ, Song Q, Lan HY (1996) Modulators of crescentic glomerulonephritis. J Am Soc Nephrol 7: 2271-2276.
15. Tipping PG, Kitching AR, Cunningham MA, Holdsworth SR (1999) Immunopathogenesis of crescentic glomerulonephritis. Curr Opin Nephrol Hypertens 8: 281-286.
16. Floege J, Topley N, Resch K (1991) Regulation of mesangial cell proliferation. Am J Kidney Dis 17: 673-676.
17. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, et al. (1992) Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297-309.
18. Okuda S, Languino LR, Rusihi E, Border WA (1990) Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86: 453-462.
19. Meltzer M, Franklin EC (1966) Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 40: 828-836.
20. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N (1966) Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with
Simulation: Haas C, Singh D, Kohan P, Soundararajan S, Aggarwal S (2015) A Rare and Atypical Case of Essential Cryoglobulinemic Glomerulonephritis with Crescents. J Nephrol Ther 5: 220. doi:10.4172/2201-0959.1000220

Page 7 of 7

rheumatoid factor activity. Am J Med 40: 837-856.
21. Ramos-Casals M, Stone JH, Cid MC, Bosch X (2012) The cryoglobulinaemias. Lancet 379: 348-360.
22. Ferri C, Sebastiani M, Giugliori D, Cazzato M, Longombardo G, et al. (2004) Mixed cryoglobulinaemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33: 357-374.
23. Trejo O, Ramos-Casals M, Garcia-Carrasco M, Yagüe J, Jiménez S, et al. (2001) Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 80: 252-262.
24. Tedeschi A, Baraté C, Minola E, Morra E (2007) Cryoglobulinemia. Blood Rev 21: 183-200.
25. Brouet JC, Claudel JP, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57: 775-788.
26. Salish S, Rajesh R, George K, Elango EM, Unni VN (2008) Membranoproliferative glomerulonephritis with essential cryoglobulinemia. Indian J Nephrol 18: 80-82.
27. Okura T, Jotoku M, Miyoshi K, Enomoto D, Kurata M, et al. (2009) Case of membranoproliferative glomerulonephritis due to essential cryoglobulinemia without hepatitis C virus infection. Geriatr Gerontol Int 9: 92-96.
28. Sargur R, White P, Egner W (2010) Cryoglobulin evaluation: best practice? Ann Clin Biochem 47: 8-16.
29. Mizuochi T, Pastone Y, Shikata K, Kuroki A, Kikuchi S, et al. (2001) Role of galactosylation in the renal pathogenicity of murine immunoglobulin G3 monoclonal cryoglobulins. Blood 97: 3537-3543.
30. Rozin M, Lewin M, Braun-Moscovici Y, Izhak OB, Bergman R, et al. (2006) Essential mixed cryoglobulinemia type II. Clin Exp Rheumatol 24: 329-332.
31. Sansonno D, Dammacco F (2005) Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex reactions. Lancet Infect Dis 5: 227-236.
32. Di Stasio E, Bizzarri P, Casato M, Galtieri A, Fiorilli M, et al. (2004) Cl- regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation. Clin Chem Lab Med 42: 614-620.
33. Smith KD, Alpers CE (2005) Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 14: 396-403.
34. D'Amico G, Colasanti G, Ferrario F, Sinico RA (1989) Renal involvement in essential mixed cryoglobulinaemia. Kidney Int 35: 1004-1014.
35. Roccaletto D, Isidoro C, Mazzuco G, Mesiti A, Quattrcchio G, et al. (1993) Role of monocytes in cryoglobulinemia-associated nephritis. Kidney Int 43: 1150-1155.
36. Fiorini G, Bernasconi P, Sinico RA, Chianese R, Pozzi F, et al. (1986) Increased frequency of antibodies to ubiquitous viruses in essential mixed cryoglobulaemia. Clin Exp Immunol 64: 65-70.
37. Fiorini GF, Sinico RA, Winears C, Custode P, De Giuli-Morghen C, et al. (1988) Persistent Epstein-Barr virus infection in patients with type II essential mixed cryoglobulinaemia. Clin Immunol Immunopathol 47: 262-269.
38. Ferri C (2008) Mixed cryoglobulinemia. Orphanet J Rare Dis 3: 25.
39. Bombardieri S, Ferri C, Migliorini P, Pontrandolfo A, Puccetti A, et al. (1986) Cryoglobulins and immune complexes in essential mixed cryoglobulinemia. Ric Clin Lab 16: 281-288.
40. Ferri C, Zignego AL, Pileri SA (2002) Cryoglobulins. J Clin Pathol 55: 4-13.
41. La Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, et al. (1995) Mixed cryoglobulinaemia as a possible preneoplastic disorder. Arthritis Rheum 38: 1859-1860.
42. Vallat JM, Desproges-Gotteron R, Leboutet MJ, Loubet A, Gualde N, et al. (1980) Cryoglobulinemic neuropathy: a pathological study. Ann Neurol 8: 179-185.
43. Saadoun D, Sellam J, Ghilani-Dalbin P, Crevel R, Piette JC, et al. (2006) Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 166: 2101-2108.
44. Quartuccio L, Fabris M, Salvin S, Isola M, Soldano F, et al. (2007) Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis. Rheumatology (Oxford) 46: 1657-1661.
45. Vitali C, Ferri C, Nasti P, La Civita L, Mazzantini M, et al. (1994) Hypercomplementaemia as a marker of the evolution from benign to malignant B cell proliferation in patients with type II mixed cryoglobulinaemia. Br J Rheumatol 33: 791-792.
46. De Vecchi A, Montagnino G, Pozzi C, Taranint A, Locatelli F, et al. (1983) Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 19: 221-227.
47. Ferri C, Cacoub P, Mazzaro C, Roccacattelo D, Scaini P, et al. (2011) Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 11: 48-55.
48. Zaja J, De Vera S, Mazzaro C, Zaccos D, Damiani D, et al. (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101: 3827-3834.
49. Ben-Bassat M, Boner G, Rosenfeld J, Pick AI, Kahana M, et al. (1983) The clinicopathologic features of cryoglobulinemic nephropathy. Am J Clin Pathol 79: 147-156.